Frontiers in Immunology (May 2023)
Corrigendum: The role of 18F−FDG PET in predicting the pathological response and prognosis to unresectable HCC patients treated with lenvatinib and PD-1 inhibitors as a conversion therapy
- Guanyun Wang,
- Guanyun Wang,
- Wenwen Zhang,
- Xiaohui Luan,
- Xiaohui Luan,
- Zhanbo Wang,
- Jiajin Liu,
- Xiaodan Xu,
- Jinming Zhang,
- Baixuan Xu,
- Shichun Lu,
- Ruimin Wang,
- Guangyu Ma
Affiliations
- Guanyun Wang
- Department of Nuclear Medicine, The First Medical Centre, Chinese People’s Liberation Army (PLA) General Hospital, Beijing, China
- Guanyun Wang
- Nuclear Medicine Department, Beijing Friendship Hospital, Capital Medical University, Beijing, China
- Wenwen Zhang
- Faculty of Hepato-Pancreato-Biliary Surgery, Chinese People’s Liberation Army (PLA) General Hospital/Institute of Hepatobiliary Surgery of Chinese People’s Liberation Army/Key Laboratory of Digital Hepetobiliary Surgery, People’s Liberation Army, Beijing, China
- Xiaohui Luan
- Department of Nuclear Medicine, The First Medical Centre, Chinese People’s Liberation Army (PLA) General Hospital, Beijing, China
- Xiaohui Luan
- Graduate School, Medical School of Chinese People’s Liberation Army (PLA), Beijing, China
- Zhanbo Wang
- Department of Pathology, The First Medical Centre, Chinese People’s Liberation Army (PLA) General Hospital, Beijing, China
- Jiajin Liu
- Department of Nuclear Medicine, The First Medical Centre, Chinese People’s Liberation Army (PLA) General Hospital, Beijing, China
- Xiaodan Xu
- Department of Nuclear Medicine, The First Medical Centre, Chinese People’s Liberation Army (PLA) General Hospital, Beijing, China
- Jinming Zhang
- Department of Nuclear Medicine, The First Medical Centre, Chinese People’s Liberation Army (PLA) General Hospital, Beijing, China
- Baixuan Xu
- Department of Nuclear Medicine, The First Medical Centre, Chinese People’s Liberation Army (PLA) General Hospital, Beijing, China
- Shichun Lu
- Faculty of Hepato-Pancreato-Biliary Surgery, Chinese People’s Liberation Army (PLA) General Hospital/Institute of Hepatobiliary Surgery of Chinese People’s Liberation Army/Key Laboratory of Digital Hepetobiliary Surgery, People’s Liberation Army, Beijing, China
- Ruimin Wang
- Department of Nuclear Medicine, The First Medical Centre, Chinese People’s Liberation Army (PLA) General Hospital, Beijing, China
- Guangyu Ma
- Department of Nuclear Medicine, The First Medical Centre, Chinese People’s Liberation Army (PLA) General Hospital, Beijing, China
- DOI
- https://doi.org/10.3389/fimmu.2023.1219757
- Journal volume & issue
-
Vol. 14
Abstract
No abstracts available.Keywords
- unresectable hepatocellular carcinoma
- conversion therapy
- major pathological response
- prognosis
- 18F-FDG PET
